摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(±)-1-O-benzyl-2,3:5,6-di-O-isopropylidene-myo-inositol | 58706-24-4

中文名称
——
中文别名
——
英文名称
(±)-1-O-benzyl-2,3:5,6-di-O-isopropylidene-myo-inositol
英文别名
(±)-2,3:5,6-di-O-isopropylidene-1-O-benzyl-myo-inositol;(±)-3-O-benzyl-1,2:4,5-di-O-isopropylidene-myo-inositol;(+/-)-1-O-benzyl-2,3:5,6-di-O-isopropylidene-myo-inositol;(+/-)-3-O-benzyl-1,2:4,5-di-O-isopropylidene-myo-inositol;1-O-benzyl-2,3:5,6-di-O-isopropylidene-myo-inositol;3-O-benzyl-1,2:4,5-di-O-isopropylidene-myo-inositol;(3aS,4S,4aR,7aR,8S,8aR)-8-Benzyloxy-2,2,6,6-tetramethyl-hexahydro-benzo[1,2-d;4,5-d']bis[1,3]dioxol-4-ol
(±)-1-O-benzyl-2,3:5,6-di-O-isopropylidene-myo-inositol化学式
CAS
58706-24-4;58769-25-8;98974-91-5;111466-16-1
化学式
C19H26O6
mdl
——
分子量
350.412
InChiKey
KWQJPCFJDMBLIR-WBAHDQRJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.99
  • 重原子数:
    25.0
  • 可旋转键数:
    3.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    66.38
  • 氢给体数:
    1.0
  • 氢受体数:
    6.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    (±)-1-O-benzyl-2,3:5,6-di-O-isopropylidene-myo-inositol 在 palladium on activated charcoal 吡啶盐酸四丁基溴化铵 、 sodium hydride 、 二正丁基氧化锡对甲苯磺酸 作用下, 以 甲醇N,N-二甲基甲酰胺丙酮 为溶剂, 反应 22.5h, 生成
    参考文献:
    名称:
    The synthesis and resolution of (±)-1,5,6-tri-O-benzyl-myo-inositol
    摘要:
    Racemic 1,5,6-tri-O-benzyl-myo-inositol was prepared by five routes and converted into 1,5,6-tri-O-benzyl-2,3-O-isopropylidene-myo-inositol, the camphanates of which were readily separated by chromatography. The absolute configurations of the chiral derivatives were established by their conversion into the known chiral 1,4,5,6-tetra-O-benzyl-myo-inositols. 1D-1,5,6-Tri-O-benzyl-2,3-O-isopropylidene-myo-inositol was converted into 1D-1,3,5,6-tetra-O-benzyl-myo-inositol and thence into 1D-2,4-di-O-methyl-myo-inositol. 1D-1,5,6-Tri-O-benzyl-myo-inositol was converted into 1D-1,2,5,6-tetra-O-benzyl-myo-inositol, the diacetate of which is a chiral analogue of "thermosalient crystals". The potential of the above compounds for the synthesis of natural products is surveyed.
    DOI:
    10.1016/0008-6215(90)80132-m
  • 作为产物:
    描述:
    Inositol 在 sodium hydride 、 对甲苯磺酸三乙胺 作用下, 以 乙醇二甲基亚砜N,N-二甲基甲酰胺丙酮 、 mineral oil 为溶剂, 反应 5.5h, 生成 (±)-1-O-benzyl-2,3:5,6-di-O-isopropylidene-myo-inositol
    参考文献:
    名称:
    Synthesis and in vitro anticancer activity evaluation of novel bioreversible phosphate inositol derivatives
    摘要:
    The chemistry and biology of phosphorylated inositols have become intense areas of research during the last two decades due to their involvement in various cellular signaling processes. However, the metabolic instability by phosphatases or kinases and poor penetration make it difficult to become a drug used in the clinic. The bioreversible protection technique can enhance membrane penetration characteristics and increase the stability of phosphorylated inositols against enzymatic degradation and is applied widely in drug discovery and development. In this paper, we described the design and synthesis of 22 bioreversible phosphotriester inositols, along with the initial antitumor activity results. Most compounds exhibited significant cytotoxic activity against human cancer cell lines A549, MDA-MB-231 and HeLa, but lower cellular toxicity on normal cell MCF10A in comparison with Cisplatin. These compounds can be used as probes to study the mechanism of intracellular signal transduction mediated by phosphate inositol or as leads of phosphate inositol drugs in the clinic. (C) 2015 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2015.01.064
点击查看最新优质反应信息

文献信息

  • Resolution of Orthogonally Protected <i>myo</i>-Inositols with Novozym 435 Providing an Enantioconvergent Pathway to Ac<sub>2</sub>PIM<sub>1</sub>
    作者:Alastair M. M. Lee、Gavin F. Painter、Benjamin J. Compton、David S. Larsen
    DOI:10.1021/jo5019188
    日期:2014.11.21
    4-dimethoxyphenyl)benzyl, propyl, and propargyl protection at O-6 in combination with either allyl or benzyl groups at O-3. Bulky protecting groups slow the rate of acetylation. No reaction was observed for 3,6-di-O-triisopropylsilyl-1,2-O-isopropylidene-myo-inositol. The utility of this methodology was demonstrated by the first reported synthesis of an Ac2PIM1 (9), which used both enantiomers of the resolved
    正交保护的手性肌肉肌醇衍生物是更高阶的重要中间体肌醇含肌醇化合物。这里,通过使用固定化酶的Novozym 435以有效地催化5的乙酰化- [R的外消旋1,2-构成的对映体直径:异亚丙基肌醇-inositols在O-3和O-6是化学上和空间上具有多样的保护基团描述。丙基,苄基,4--,4-甲氧基-,4-硝基和4-(3,4-二甲氧基苯基)苄基,丙基和炔丙基在O-6的保护下与任何一个丙基结合均能成功解决拆分问题或O-3处的苄基。庞大的保护基团会降低乙酰化速度。3,6-di-未观察到反应Ø -triisopropylsilyl -1,2- Ø异亚丙基肌醇肌醇。该方法的实用性通过首次报道的Ac 2 PIM 1(9)合成得到证明,该化合物使用了拆分后的3- O-丙基-6- O-苄基-1,2- O-异亚丙基-肌醇的两种对映体。-肌醇的融合合成。
  • Improved preparation of acetals of myo-inositol and its (±)-1-benzyl ether: conformational analysis of di-O-isopropylidene-myo-inositol derivatives
    作者:Roberto Fernandez de la Pradilla、Carlos Jaramillo、Jesus Jimenez-Barbero、Manuel Martin-Lomas、Soledad Penades、Amparo Zapata
    DOI:10.1016/0008-6215(90)84052-v
    日期:1990.10
    myo -inositol with 3–5 equiv. of 2-methoxypropene or 2,2-dimethoxypropane in methyl sulfoxide or N,N -dimethylformamide gave mixtures of the 1,2:4,5-, 1,2:5,6-, and 1,2:3,4-di- O -isopropylidene derivatives with little or none of the 1,2:3,4:5,6-triacetal 5 . With ≈ 7 equiv. of 2-methoxypropene in methyl sulfoxide-hexane, 70% of 5 was obtained. Kinetic acetonation of 1- O -benzyl- myo -inositol gave
    摘要肌醇与3-5当量的酸催化反应。将2-甲氧基丙烯2,2-二甲氧基丙烷甲基亚砜或N,N-二甲基酰胺中得到1,2,4,5-,1,2:5,6-和1,2:3,4-的混合物几乎没有或没有1,2:3,4:5,6-三缩醛5的二-O-异亚丙基衍生物。≈7当量 在甲基亚砜-己烷中得到2-甲氧基丙烯,得到5的70%。1-O-苄基-肌醇的动力学丙酮化主要产生3,4:5,6-二缩醛,而热力学条件主要产生2,3:5,6-二缩醛。1-O-苄基-2,3:4,5-二-O-异亚丙基-肌醇是次要产品,主要存在于非极性溶剂的椅子构型和极性偏斜的船形结构中。溶剂,而6-乙酸盐仅采用斜舟构象。
  • Regioselective functionalizations and conformational studies of di-O-isopropylidene-myo-inositol derivatives
    作者:Sung-Kee Chung、Youngha Ryu
    DOI:10.1016/0008-6215(94)84082-2
    日期:1994.5
    in IR and 1H NMR spectra, and the HO-3 group was identified as the hydrogen-bonding donor in 5 and 6. In their crystalline states, diol 5 prefers a chair conformation and diol 6 a twist boat (skew) conformation. Both compounds appear to have substantial populations of chair conformations in the gas and solution phases, on the basis of the MM-2 energy minimizations and comparisons of vicinal coupling
    摘要(±)-1,2:4,5-二-O-异亚丙基-肌醇(5)和(±)-1,2:5,6-二-O-异亚丙基-肌醇(6)在特定条件下,在HO-3上的烷基化,酰化和甲硅烷基化反应分别优先于HO-6和HO-4进行区域选择性功能化。分子内键的存在在IR和1H NMR光谱中是明显的,并且HO-3基团被鉴定为5和6中的键供体。在它们的结晶态中,二醇5更喜欢椅子构型,而二醇6更喜欢扭曲。船(偏斜)构象。两种化合物在气相和溶液相中似乎都具有大量的椅子构象,基于MM-2的能量最小化和在1H NMR光谱(在CDCl3和Me2SO-d6中)观察到的邻位耦合常数的比较,并根据晶体和MM-2构型进行计算。建议作为观察到的选择性的解释,HO-3基团的动力学酸性可通过其与顺式-邻位的分子内键结合而增强,或3-醇盐的亲核性可由于其相互作用而增强。与顺式邻位作用相似,其作用方式类似于贯穿空间的α效应。
  • Bio-inspired synthesis of rare and unnatural carbohydrates and cyclitols through strain driven epimerization
    作者:Raja Mohanrao、Aromal Asokan、Kana M. Sureshan
    DOI:10.1039/c4cc00868e
    日期:——

    Bio-inspired isomerization of carbohydrates and cyclitols to their rare and unnatural isomers, through strain-driven epimerization of trans-ketals to cis-ketals, is introduced.

    通过通过对碳水化合物环己醇进行仿生异构化,通过应变驱动的将反式-缩醛异构化为顺式-缩醛,引入了它们罕见且非自然的异构体。
  • Gigg, Jill; Gigg, Roy; Payne, Sheila, Journal of the Chemical Society. Perkin transactions I, 1987, p. 423 - 430
    作者:Gigg, Jill、Gigg, Roy、Payne, Sheila、Conant, Robert
    DOI:——
    日期:——
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫